卡维地洛对舒张性心力衰竭患者血浆脑钠肽及心功能的影响

Effects of Carvedilol Therapy for Plasma Brain Natriuretic Peptide and Heart Function in Patients with Diastolic Heart Failure

目的评价卡维地洛对舒张性心力衰竭(DHF)患者血浆脑钠肽及心功能的影响。方法 46例DHF患者,按入院顺序随机分为卡维地洛治疗组23例,对照组23例。两组均给予常规治疗,包括血管紧张素转换酶抑制剂、钙离子拮抗剂及利尿剂,治疗组在此治疗基础上加用卡维地洛6.25mg,2次/d,逐渐增至25mg,2次/d。治疗4周后随访8周,检测两组患者血浆脑钠肽浓度及左室射血分数(LVEF)。结果 8周后随访,与对照组比较,治疗组血浆脑钠肽浓度降低显著(P<0.01),LVEF增加明显(P<0.01),未见严重不良反应。结论卡维地洛能明显降低DHF患者血浆脑钠肽浓度,改善心功能,且安全有效。

Objective To assess the effects of carvedilol treatment for plasma brain natriuretic peptide and heart function in patients with diastolic heart failure（DHF）.Methods 46 patients with DHF were randomly divided into carvediolo treatment group（n=23）,control group（n=23）,and both groups were given conventional treatment,including angiotensin-converting enzyme inhibitors,calcium channel antagonists and diuretics.For treatment group,carvedilol table was administered（12.5mg/day）,and the dosage gradually increased 50mg/d.The treatment lasted for 4 weeks,and then plasma brain natriuretic peptide（BNP） concentration and left ventricular ejection fraction were observed after 8-week follow-up.Results After 8-week follow-up,treatment group showed significant decrease in BNP compared with control group（P0.01）,and significant increase in left ventricular ejection fraction（P0.01）.No serious adverse reactions occurred.Conclusion Carvedilol can significantly reduce plasma BNP level in patients with DHF;improve heart function as a safe and effective measurement for DHF.